Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report

BACKGROUND: Gallbladder cancer typically follows an aggressive course, with chemotherapy the standard of care for advanced disease; complete remissions are rarely encountered. The epidermal growth factor receptor (EGFR) is a promising therapeutic target but the activity of single agent oral EGFR tyr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mody, Kabir, Strauss, Edward, Lincer, Robert, Frank, Richard C
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972285/
https://www.ncbi.nlm.nih.gov/pubmed/20961434
http://dx.doi.org/10.1186/1471-2407-10-570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972285/
https://www.ncbi.nlm.nih.gov/pubmed/20961434
http://dx.doi.org/10.1186/1471-2407-10-570

Ejemplares similares